Esoxium 40

Indicated for relieving chronic heartburn and GERD symptoms, healing and maintaining healing of erosive esophagitis, H. pylori eradication in combination therapy, Zollinger-Ellison Syndrome, acid-related dyspepsia, and peptic ulcers.

Acts as a proton pump inhibitor suppressing gastric acid secretion via specific (H⁺/K⁺-ATPase) inhibition. Administered as enteric-coated pellets reaching peak plasma levels (Cₘₐₓ) at approximately 1.5 hours.

Oral: Erosive Esophagitis healing 20-40 mg once daily for 4-8 weeks; maintenance 20 mg once daily. GERD 20 mg once daily. H. pylori eradication: 40 mg once daily for 10 days. Zollinger-Ellison: 20-80 mg daily. IV injection/infusion: 10 mg to 80 mg based on condition and age.

Frequently reported adverse events include headache, diarrhea, nausea, flatulence, abdominal pain, constipation, and dry mouth. Safety profile remains consistent during long-term treatment up to 12 months.

No adequate and well-controlled studies in pregnant women. Animal studies revealed no teratogenic effects. Use during pregnancy only if clearly necessary.

Symptomatic response does not preclude gastric malignancy. Long-term use may be associated with bone fractures and mineral deficiencies (e.g., magnesium). Use cautiously in severe hepatic impairment.

Symptoms of acute toxicity include reduced motor activity, changes in respiratory frequency, tremor, ataxia, and intermittent clonic convulsions. Management should be symptomatic and supportive.

Store at a temperature not exceeding 30°C in a dry place. Protect from light and moisture. Keep out of the reach of children.